Neuraxis Inc. Overview

Neuraxis, Inc., a medical technology company headquartered in Carmel, United States, is making strides in the health care sector with its focus on neuromodulation therapies. The company is dedicated to developing innovative treatments for chronic and debilitating conditions affecting both children and adults worldwide. Neuraxis is publicly traded on the NYSE American under the ticker symbol “NXS.”

Recent Financial Performance

As of May 4, 2025, Neuraxis Inc. reported a close price of $2.05 per share. The company’s stock has experienced significant volatility over the past year, with a 52-week high of $3.78 on November 13, 2024, and a 52-week low of $1.33 on April 15, 2025. The market capitalization of Neuraxis stands at approximately $16.67 million.

Financial Ratios and Metrics

The company’s price-to-earnings (P/E) ratio is currently at -1.9, indicating that it is not generating positive earnings. This metric reflects the challenges faced by the company in achieving profitability amidst its ongoing research and development efforts.

Company Focus and Mission

Neuraxis Inc. is committed to advancing neuromodulation therapies, a field that involves the use of electrical stimulation to modulate nervous system activity. The company’s mission is to provide effective treatments for patients suffering from chronic conditions, with a particular emphasis on pediatric and adult populations. By leveraging cutting-edge technology and research, Neuraxis aims to improve the quality of life for individuals globally.

For more information about Neuraxis Inc. and its initiatives, visit their website at www.neuraxis.com .